Logo

Takeda to Merge with Syrrx

Feb 07, 2005

NEW YORK, Feb. 7 (GenomeWeb News) - Takeda Pharmaceutical, of Osaka, Japan, said today it has signed a deal to merge with Syrrx. The new company will be called the Takeda Group.

 

According to Takeda, the merger will combine Syrrx's high-throughput X-ray crystallography technology and R&D efforts with Takeda's own pipeline, and establish a discovery research presence for Takeda in the US. San Diego-based Syrrx will become part of Takeda's global discovery research network together with its existing discovery centers in Osaka and Tsukuba.

 

Terms of the deal, which is still subject to customary closing conditions, were not disclosed.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.